What happened
On August 31, ST Renfu (600079) announced that its controlling subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., received an Acceptance Notice from the National Medical Products Administration for its drug registration marketing application for pregabalin extended-release tablets.
The drug is classified as a chemical drug Category 3 and is intended to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.
Yichang Renfu has invested approximately 62 million yuan in research and development for this project so far, and Minenet data shows pregabalin formulation sales nationwide reached about 780 million yuan in 2025.
Why it matters
The acceptance of the application marks a regulatory step toward potential market entry for this pregabalin formulation, and the sizable 2025 sales figure suggests significant commercial opportunity if approved.
The company's strong mid-2026 financial results, with revenue of 12.061 billion yuan and attributable net profit of 1.330 billion yuan, may provide resources to support the drug's development and launch.
Key facts
ST Renfu's controlling subsidiary Yichang Renfu received an Acceptance Notice for pregabalin extended-release tablets from the National Medical Products Administration.
The drug is a chemical drug Category 3 product for diabetic peripheral neuropathy-related neuropathic pain and postherpetic neuralgia.
Cumulative R&D investment in the project is approximately 62 million yuan; pregabalin formulation sales nationwide were about 780 million yuan in 2025.
In the first half of 2026, ST Renfu reported revenue of 120.61 billion yuan and net profit attributable to the parent of 13.30 billion yuan.
What to watch next
Investors will likely track the progress of the regulatory review and whether the drug ultimately receives marketing approval.
Market reaction and competition dynamics in the pregabalin segment may also be closely observed given the product's potential market size.